Occurrence of gastric cancer after laparoscopic Roux-en-Y gastric bypass: a systematic review.
10.3760/cma.j.cn441530-20211221-00515
- Author:
Shi Liang DONG
1
;
Ya Lun LIANG
1
;
Cun Chuan WANG
1
;
Zhi Yong DONG
1
Author Information
1. Department of Gastrointestinal Surgery, Department of Bariatric Surgery, the First Affiliated Hospital, Jinan University, Guangzhou 510630, China.
- Publication Type:Systematic Review
- MeSH:
Esophageal Neoplasms/surgery*;
Gastric Bypass/adverse effects*;
Humans;
Laparoscopy;
Obesity/surgery*;
Obesity, Morbid/surgery*;
Stomach Neoplasms/surgery*
- From:
Chinese Journal of Gastrointestinal Surgery
2022;25(9):834-839
- CountryChina
- Language:Chinese
-
Abstract:
Laparoscopic Roux-en-Y gastric bypass (RYGB) is an important obesity surgery. The risk of remnant gastric cancer after RYGB for obesity is gaining growing attention from bariatric surgeons and patients with obesity. This systematic review included articles from major databases internationally and domestically that specifically described the remnant gastric cancer after RYGB intervention, a total of 21 cases was subsequently analyzed. The average median time from post-operative RYGB to diagnosis of gastric cancer was 11 years (1-28 years), the duration of gastric cancer symptoms lasted 7 days to 6 years, abdominal pain is the most common (71.4%), especially in the upper abdomen (33.3%), followed by nausea and vomiting (33.3%), over-weight loss (33.3%), and abdominal bloating (28.6%), etc. Neoplasm location was reported to occur in the antrum or the pre-pyloric region (71.4%), with adenocarcinoma being the most common tumor histology observed (71.4%), tumor stage III-IV as the most diagnosed, 38.1% of tumor were deemed to be unresectable, 52.4% of the patients performed subtotal gastrectomy and lymphadenectomy. In addition, a global article investigating the occurrence of esophageal gastric cancer after RYGB in 64 cases revealed the common preoperative medical history include smoking habits (37.5%), alcohol issues (14.0%), GERD (86.0%), presence with Barret esophagus (10.9%), patients that has other malignant tumor medical history (6.3%), first-degree relatives (6.3%), or other family members with gastric esophagus cancer family history. Although the incidence of gastric cancer after RYGB is rare, the increasing prevalence of gastric cancer development is one of great concern. A rise in clinical cases of patients treated with RYGB presents a target for future studies. Risk of gastric cancer after RYGB should be evaluated and considered in high-risk cases.
